Targeting Myeloid-Derived Suppressor Cells to Bypass Tumor-Induced Immunosuppression.

Fleming V, Hu X, Weber R, Nagibin V, Groth C, Altevogt P, Utikal J, Umansky V. · 2018

Read Targeting Myeloid-Derived Suppressor Cells to Bypass Tumor-Induced Immunosuppression. by Fleming V, Hu X, Weber R, Nagibin V, Groth C, Altevogt P, Utikal J, Umansky V. (2018) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5840207.txt.

Description

Fleming and co-authors survey ways to disarm myeloid-derived suppressor cells in cancer. Their review appeared in Frontiers in Immunology. These immature myeloid cells gather in tumors and mute the immune response. Their numbers track with worse outcomes and failed immunotherapy.

The cells starve T cells of key amino acids. They flood the scene with suppressive signals and nitric oxide. They also build blood vessels and prepare distant soil for metastasis. Trials now test three counters: blocking their suppression, stopping their travel, and wiping them out. Pairing those moves with checkpoint drugs is the larger hope.

Catalog record

CREATORFleming V, Hu X, Weber R, Nagibin V, Groth C, Altevogt P, Utikal J, Umansky V.
YEAR2018
COLLECTIONPAPERS
FORMATTXT
FILE SIZE52 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC5840207

Browse the full library · About the Tower of Babel